Peptide therapy TikTok trends: separating hype from actual evidence

What did @kellyferrobeauty actually say?

Kelly says she has been on "Trizzy" (tirzepatide) for roughly two and a half months, lost about 20 pounds, noticed her face looked slimmer almost immediately, felt less hungry, and, most surprisingly to her, became "emotionally stable more than I was." She also recommends working with a provider, at least initially. That last point is worth noting because a lot of creators skip it entirely.

She frames everything as personal experience and is explicit that this is not medical advice. She does not claim tirzepatide treats a disease, does not mention a dose, and does not tell viewers to stack it with anything. As far as TikTok peptide content goes, this is relatively responsible. But "personal experience" disclaimers do not neutralize physiologically specific claims, and a few of her observations deserve a closer look.

Does the science back this up?

On weight loss, yes, broadly. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants on the highest dose of tirzepatide lost an average of 20.9% of body weight over 72 weeks. Two and a half months is early in that timeline, but 20 pounds in that window is plausible depending on starting weight and dose.

On facial slimming, there is no randomized trial studying "face shrinkage" specifically, but significant early fat redistribution from caloric deficit is well-documented. The phenomenon sometimes called "Ozempic face" in GLP-1 coverage is real in the sense that rapid fat loss affects the face, though the framing of "insulin resistance" in her face is not really how that works anatomically.

On emotional stability, this is the most scientifically complex claim. GLP-1 receptors are expressed in the brain, including areas involved in reward and affect regulation. Early research, including a 2023 review by Leggio et al. in Nature Medicine, points to possible neuropsychiatric effects of GLP-1 receptor agonists. But tirzepatide also acts on GIP receptors, and the central nervous system effects of dual agonism are not well characterized yet. Her observation is not implausible, but it is far ahead of the evidence.

What did they get wrong (or right)?

She got the weight loss trajectory roughly right, and her recommendation to use a provider is genuinely good advice. She deserves credit for both.

What she gets wrong, or at least oversimplifies, is the insulin resistance framing. She says "I don't know if I was insulin resistance before but my face shrunk instantly." Facial changes from tirzepatide are more likely explained by rapid caloric restriction and early water weight loss than by resolving insulin resistance specifically. Insulin resistance does not primarily manifest as facial puffiness in a clinically documented way. That said, tirzepatide does improve insulin sensitivity (Jastreboff et al., 2022), so her overall metabolic picture may well have changed.

The emotional stability claim is where things get speculative. She is honest that she does not understand why it is happening, which is actually the correct epistemic position. Viewers who take this as a confirmed mood benefit of tirzepatide would be going further than the data currently supports.

What should you actually know?

Tirzepatide is FDA-approved under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It is also approved as Mounjaro for type 2 diabetes. Compounded versions exist and are not the same as the approved brand, and patients should understand that distinction before sourcing either.

The neuropsychiatric angle is genuinely interesting and under-studied. The FDA added a warning about suicidal ideation to semaglutide labels in 2023 for ongoing monitoring, though causality was not established. The mood effects Kelly describes are positive, but anyone experiencing significant mood changes on a GLP-1 or GIP agonist should flag that with their prescriber, not just post about it.

Side effects she does not mention include nausea, vomiting, gastroparesis risk, and potential thyroid C-cell concerns (flagged in animal studies, not confirmed in humans). Her "smooth sailing" framing undersells that some people discontinue tirzepatide due to GI side effects. A provider relationship, as she recommends, is the appropriate place to manage all of this.